CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
clobetasol propionatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00828464
NCT00828464Phase 4Completed
CompareCT.gov

An Open Label Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for the Condition of Chronic Hand Dermatitis

Stiefel, a GSK Company·interventional·Posted Jan 26, 2009·Updated Oct 3, 2012

In Brief

A Phase 4 clinical trial evaluating clobetasol propionate for Hand Dermatosis. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of the study is to assess the safety, efficacy and tolerability of Clobetasol propionate foam in subjects with chronic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHand Dermatosis
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 26, 2009
Enrollment StartOct 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.4 years ago

Interventions

clobetasol propionatedrug

Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.